Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status  Phase of research How it helps Latest publication
C2 (IgG)
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/15/2021
Hydroxyitraconazole
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
VS10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
mAb 2-36
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021
S-Trimer
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/01/2021
1212C2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Rac5c
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/04/2021
C1632
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/22/2021
Genz-667161
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Genz-123346
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
(S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/10/2021
mAb 2-7
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021
VHH WE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
aRBD-2-7
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/03/2021
VHH EW
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
ΔCS-PP
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/02/2021
hACE221-55A36K-F40E
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
VHH VE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021